Literature DB >> 25779951

Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Following Flu-TBI versus TLI-ATG Conditioning.

Muriel Hannon1, Yves Beguin2, Grégory Ehx3, Sophie Servais2, Laurence Seidel4, Carlos Graux5, Johan Maertens6, Tessa Kerre7, Coline Daulne3, Muriel de Bock3, Marianne Fillet3, Aurélie Ory8, Evelyne Willems8, André Gothot9, Stéphanie Humblet-Baron3, Frédéric Baron2.   

Abstract

PURPOSE: A conditioning regimen for allogeneic hematopoietic cell transplantation (HCT) combining total lymphoid irradiation (TLI) plus anti-thymocyte globulin (ATG) has been developed to induce graft-versus-tumor effects without graft-versus-host disease (GVHD). EXPERIMENTAL
DESIGN: We compared immune recovery in 53 patients included in a phase II randomized study comparing nonmyeloablative HCT following either fludarabine plus 2 Gy total body irradiation (TBI arm, n = 28) or 8 Gy TLI plus ATG (TLI arm, n = 25).
RESULTS: In comparison with TBI patients, TLI patients had a similarly low 6-month incidence of grade II-IV acute GVHD, a lower incidence of moderate/severe chronic GVHD (P = 0.02), a higher incidence of CMV reactivation (P < 0.001), and a higher incidence of relapse (P = 0.01). While recovery of total CD8(+) T cells was similar in the two groups, with median CD8(+) T-cell counts reaching the normal values 40 to 60 days after allo-HCT, TLI patients had lower percentages of naïve CD8 T cells. Median CD4(+) T-cell counts did not reach the lower limit of normal values the first year after allo-HCT in the two groups. Furthermore, CD4(+) T-cell counts were significantly lower in TLI than in TBI patients the first 6 months after transplantation. Interestingly, while median absolute regulatory T-cell (Treg) counts were comparable in TBI and TLI patients, Treg/naïve CD4(+) T-cell ratios were significantly higher in TLI than in TBI patients the 2 first years after transplantation.
CONCLUSIONS: Immune recovery differs substantially between these two conditioning regimens, possibly explaining the different clinical outcomes observed (NCT00603954). ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25779951     DOI: 10.1158/1078-0432.CCR-14-3374

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  14 in total

Review 1.  Reconstitution of adaptive immunity after umbilical cord blood transplantation: impact on infectious complications.

Authors:  Sophie Servais; Muriel Hannon; Régis Peffault de Latour; Gérard Socie; Yves Beguin
Journal:  Stem Cell Investig       Date:  2017-05-25

Review 2.  Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Frédéric Baron; Mohamad Mohty; Didier Blaise; Gérard Socié; Myriam Labopin; Jordi Esteve; Fabio Ciceri; Sebastian Giebel; Norbert Claude Gorin; Bipin N Savani; Christoph Schmid; Arnon Nagler
Journal:  Haematologica       Date:  2016-12-07       Impact factor: 9.941

Review 3.  Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.

Authors:  Jeannine S McCune; Meagan J Bemer; Janel Long-Boyle
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

Review 4.  Immune reconstitution and outcomes after conditioning with anti-thymocyte-globulin in unrelated cord blood transplantation; the good, the bad, and the ugly.

Authors:  Coco de Koning; Rick Admiraal; Stefan Nierkens; Jaap Jan Boelens
Journal:  Stem Cell Investig       Date:  2017-05-16

5.  Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation.

Authors:  Sophie Servais; Catherine Menten-Dedoyart; Yves Beguin; Laurence Seidel; André Gothot; Coline Daulne; Evelyne Willems; Loïc Delens; Stéphanie Humblet-Baron; Muriel Hannon; Frédéric Baron
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

6.  Xenogeneic Graft-Versus-Host Disease in Humanized NSG and NSG-HLA-A2/HHD Mice.

Authors:  Grégory Ehx; Joan Somja; Hans-Jörg Warnatz; Caroline Ritacco; Muriel Hannon; Loïc Delens; Gilles Fransolet; Philippe Delvenne; Joséphine Muller; Yves Beguin; Hans Lehrach; Ludovic Belle; Stéphanie Humblet-Baron; Frédéric Baron
Journal:  Front Immunol       Date:  2018-08-30       Impact factor: 7.561

7.  Naive and Stem Cell Memory T Cell Subset Recovery Reveals Opposing Reconstitution Patterns in CD4 and CD8 T Cells in Chronic Graft vs. Host Disease.

Authors:  Maria V Soares; Rita I Azevedo; Inês A Ferreira; Sara Bucar; Ana C Ribeiro; Ana Vieira; Paulo N G Pereira; Ruy M Ribeiro; Dario Ligeiro; Ana C Alho; António S Soares; Nádia Camacho; Carlos Martins; Fernanda Lourenço; Raul Moreno; Jerome Ritz; João F Lacerda
Journal:  Front Immunol       Date:  2019-03-06       Impact factor: 7.561

8.  Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood--a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Frédéric Baron; Myriam Labopin; Annalisa Ruggeri; Mohamad Mohty; Guillermo Sanz; Noel Milpied; Andrea Bacigalupo; Alessandro Rambaldi; Francesca Bonifazi; Alberto Bosi; Jorge Sierra; Ibrahim Yakoub-Agha; Josep Maria Ribera Santasusana; Eliane Gluckman; Arnon Nagler
Journal:  J Hematol Oncol       Date:  2015-10-06       Impact factor: 17.388

9.  Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease.

Authors:  Gilles Fransolet; Grégory Ehx; Joan Somja; Loïc Delens; Muriel Hannon; Joséphine Muller; Sophie Dubois; Pierre Drion; Jo Caers; Stéphanie Humblet-Baron; Philippe Delvenne; Yves Beguin; Giuseppina Conteduca; Frédéric Baron
Journal:  J Hematol Oncol       Date:  2016-07-04       Impact factor: 17.388

10.  Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease.

Authors:  Ludovic Belle; Gilles Fransolet; Joan Somja; Marilène Binsfeld; Philippe Delvenne; Pierre Drion; Muriel Hannon; Yves Beguin; Grégory Ehx; Frédéric Baron
Journal:  PLoS One       Date:  2016-12-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.